Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
PRKAR1B Monoclonal Antibody (OTI2A3), TrueMAB™, OriGene

Mouse Monoclonal Antibody
Supplier: OriGene TA502750

Description
The second messenger cyclic AMP (cAMP) mediates diverse cellular responses to external signals such as proliferation, ion transport, regulation of metabolism and gene transcription by activation of the cAMP-dependent protein kinase (cAPK or PKA). Activation of PKA occurs when cAMP binds to the two regulatory subunits of the tetrameric PKA holoenzyme resulting in release of active catalytic subunits. Three catalytic (C) subunits have been identified that each represent specific gene products. Activation of transcription upon elevation of cAMP levels results from translocation of PKA to the nucleus where it phosphorylates the transcrip- tion factor cAMP response element binding protein (CREB) on serine 133 which in turn leads to TFIIB binding to TATA-box-binding protein TBP1, thus linking phospho-CREB to the pol II transcription initiation complex.Specifications
PRKAR1B | |
Monoclonal | |
0.57 mg/mL | |
PBS with 1% BSA, 50% glycerol and 0.02% sodium azide | |
P31321 | |
PRKAR1B | |
Full length human recombit protein of human PRKAR1B produced in HEK293T cell. | |
100 μL | |
Primary | |
Human | |
Antibody | |
IgG1 |
Flow Cytometry, Immunocytochemistry, Immunofluorescence, Immunohistochemistry (Paraffin), Western Blot | |
OTI2A3 | |
Unconjugated | |
PRKAR1B | |
PRKAR1 | |
Mouse | |
Affinity Chromatography | |
RUO | |
5575 | |
-20° C, Avoid Freeze/Thaw Cycles | |
Liquid |
Product Content Correction
The Fisher Scientific Encompass Program offers items which are not part of our distribution portfolio. These products typically do not have pictures or detailed descriptions. However, we are committed to improving your shopping experience. Please use the form below to provide feedback related to the content on this product.
Product Title
Spot an opportunity for improvement?Share a Content Correction